secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-09-22T20:41:04+00:00
Accession:  0001193125-26-398015
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme completes $1.5B 1.50% convertible notes due 2033; repurchases existing notes
--------------------------------------------------------------------------------

- Issued $1.5B aggregate 1.50% Convertible Senior Notes due 2033; net proceeds ~$1,471.1M.
- Repurchasing $151.7M of 0.25% 2027 Notes and $220M of 1.00% 2028 Notes for ~$217M and $435.5M incl. interest.
- Spent $187.5M on capped call transactions; cap price initially $208.39/share (~90% premium).
- Initial conversion price ~$139.84/share (7.1509 shares per $1,000 principal).
- Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/0001193125-26-398015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-398015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer